Idera Pharmaceuticals (IDRA) News 4.57 $IDRA
Why Idera Pharmaceuticals, Bofi Holdings, and Eastman Kodak Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 4:15PM CDT
Following day after day of mixed economic data this week, the broad-based S&P 500 managed to muster up a solid gain on Friday after all data finally pointed in the correct direction. First off, the final Thomson Reuters/University of...
Why Idera Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals , a clinical-stage...
Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
Business Wire - Fri Mar 28, 6:15AM CDT
--IMO-8400 also demonstrates clinical proof-of-concept in psoriasis
Idera Pharmaceuticals Down 9.2%, Shares Slide into the Red (IDRA)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 9.2% to $3.81 on 1.1x average daily volume. Idera Pharmaceuticals has traded 3.7 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's 0.0%) and underperformed the S&P 500 (-9.2% to the S&P's -0.2%) during today's trading.
Is Idera's Sell-Off Premature?
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera's Phase II candidate, IMO-8400. Both drugs face a crowded marketplace for...
Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Tue Mar 25, 8:46AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Stock to Watch: Idera Pharmaceuticals Down 24.2% (IDRA)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 24.2% to $4.61 on 2.1x average daily volume. Thus far today, Idera Pharmaceuticals has traded 6.4 million shares, vs. average volume of 3.1 million shares per day. The stock has underperformed the Dow (-24.2% to the Dow's -0.2%) and underperformed the S&P 500 (-24.2% to the S&P's -0.6%) during today's trading.
Insider Buying Is On The Rise In These 4 Rallying Stocks
at The Street - Thu Mar 20, 5:16PM CDT
James Dennin, Kapitall: One way to evaluate small cap stocks is by looking for insider buying, when people on staff are buying [...]
New Highs & Stocks to Watch -- Research on Penn Virginia, Idera Pharma, US Geothermal, and First Republic Bank
PR Newswire - Wed Mar 19, 7:23AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite finished at 4,333.31, up 1.25%. The Dow Jones Industrial Average closed the session at 16,336.19, up 0.55% and the S&P 500 ended the day at 1,872.25, higher by 0.72%. The gains were broad based with 9 of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Penn Virginia Corp. (NYSE: PVA), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), US Geothermal Inc. (AMEX: HTM), and First Republic Bank (NYSE: FRC). Free technical research on PVA, IDRA, HTM and FRC can be downloaded upon signing up at:
Idera Pharmaceuticals Shares Up 20.5% Since SmarTrend's Buy Recommendation (IDRA)
Comtex SmarTrend(R) - Mon Mar 17, 5:40PM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 20.48% as of today's recent price of $6.06.
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Mar 13, 6:50AM CDT
--- Details announced for planned clinical development of IMO-8400 in polymyositis and dermatomyositis -
Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases
Business Wire - Thu Mar 13, 6:35AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. The Company plans to submit a protocol to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for a Phase 1/2 clinical trial to investigate the safety and potential utility of IMO-8400 in these two indications. This represents the execution of a previously announced strategy to expand the clinical development of IMO-8400 in orphan autoimmune disease indications. Based on the results from this study, Idera anticipates that it will pursue separate later-stage clinical trials for each indication.
Idera Pharmaceuticals names Baker Brothers Investments' executives to board
M2 - Thu Mar 13, 4:01AM CDT
Biopharmaceutical company Idera Pharmaceuticals (NasdaqCM:IDRA) disclosed on Wednesday the addition of two Baker Brothers Investments' executives to its board of directors.
Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
Business Wire - Wed Mar 12, 7:30AM CDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments' Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investments manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations.
17.7% Return Seen to Date on SmarTrend Idera Pharmaceuticals Call (IDRA)
Comtex SmarTrend(R) - Mon Mar 10, 11:18AM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 17.65% as of today's recent price of $5.92.
Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
Business Wire - Thu Mar 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Uptrend Call Working As Idera Pharmaceuticals Stock Rises 14.1% (IDRA)
Comtex SmarTrend(R) - Mon Mar 03, 9:59AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 3 weeks, Idera Pharmaceuticals has returned 14.12% as of today's recent price of $5.74.
Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston, MA.
Idera Pharmaceuticals Up 16.0% Since SmarTrend Uptrend Call (IDRA)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 2 weeks, Idera Pharmaceuticals has returned 15.98% as of today's recent price of $5.83.
Idera to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 3:02PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City.
Why Idera Pharmaceuticals, Bofi Holdings, and Eastman Kodak Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 4:15PM CDT
Following day after day of mixed economic data this week, the broad-based S&P 500 managed to muster up a solid gain on Friday after all data finally pointed in the correct direction. First off, the final Thomson Reuters/University of...
Why Idera Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals , a clinical-stage...
Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
Business Wire - Fri Mar 28, 6:15AM CDT
--IMO-8400 also demonstrates clinical proof-of-concept in psoriasis
Idera Pharmaceuticals Down 9.2%, Shares Slide into the Red (IDRA)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 9.2% to $3.81 on 1.1x average daily volume. Idera Pharmaceuticals has traded 3.7 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's 0.0%) and underperformed the S&P 500 (-9.2% to the S&P's -0.2%) during today's trading.
Is Idera's Sell-Off Premature?
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera's Phase II candidate, IMO-8400. Both drugs face a crowded marketplace for...
Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Tue Mar 25, 8:46AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Stock to Watch: Idera Pharmaceuticals Down 24.2% (IDRA)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 24.2% to $4.61 on 2.1x average daily volume. Thus far today, Idera Pharmaceuticals has traded 6.4 million shares, vs. average volume of 3.1 million shares per day. The stock has underperformed the Dow (-24.2% to the Dow's -0.2%) and underperformed the S&P 500 (-24.2% to the S&P's -0.6%) during today's trading.
Insider Buying Is On The Rise In These 4 Rallying Stocks
at The Street - Thu Mar 20, 5:16PM CDT
James Dennin, Kapitall: One way to evaluate small cap stocks is by looking for insider buying, when people on staff are buying [...]
New Highs & Stocks to Watch -- Research on Penn Virginia, Idera Pharma, US Geothermal, and First Republic Bank
PR Newswire - Wed Mar 19, 7:23AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite finished at 4,333.31, up 1.25%. The Dow Jones Industrial Average closed the session at 16,336.19, up 0.55% and the S&P 500 ended the day at 1,872.25, higher by 0.72%. The gains were broad based with 9 of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Penn Virginia Corp. (NYSE: PVA), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), US Geothermal Inc. (AMEX: HTM), and First Republic Bank (NYSE: FRC). Free technical research on PVA, IDRA, HTM and FRC can be downloaded upon signing up at:
Idera Pharmaceuticals Shares Up 20.5% Since SmarTrend's Buy Recommendation (IDRA)
Comtex SmarTrend(R) - Mon Mar 17, 5:40PM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 20.48% as of today's recent price of $6.06.
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Mar 13, 6:50AM CDT
--- Details announced for planned clinical development of IMO-8400 in polymyositis and dermatomyositis -
Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases
Business Wire - Thu Mar 13, 6:35AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. The Company plans to submit a protocol to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for a Phase 1/2 clinical trial to investigate the safety and potential utility of IMO-8400 in these two indications. This represents the execution of a previously announced strategy to expand the clinical development of IMO-8400 in orphan autoimmune disease indications. Based on the results from this study, Idera anticipates that it will pursue separate later-stage clinical trials for each indication.
Idera Pharmaceuticals names Baker Brothers Investments' executives to board
M2 - Thu Mar 13, 4:01AM CDT
Biopharmaceutical company Idera Pharmaceuticals (NasdaqCM:IDRA) disclosed on Wednesday the addition of two Baker Brothers Investments' executives to its board of directors.
Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
Business Wire - Wed Mar 12, 7:30AM CDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments' Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investments manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations.
17.7% Return Seen to Date on SmarTrend Idera Pharmaceuticals Call (IDRA)
Comtex SmarTrend(R) - Mon Mar 10, 11:18AM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 17.65% as of today's recent price of $5.92.
Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
Business Wire - Thu Mar 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Uptrend Call Working As Idera Pharmaceuticals Stock Rises 14.1% (IDRA)
Comtex SmarTrend(R) - Mon Mar 03, 9:59AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 3 weeks, Idera Pharmaceuticals has returned 14.12% as of today's recent price of $5.74.
Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston, MA.
Idera Pharmaceuticals Up 16.0% Since SmarTrend Uptrend Call (IDRA)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 2 weeks, Idera Pharmaceuticals has returned 15.98% as of today's recent price of $5.83.
Idera to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 3:02PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City.
